Fresenius Medical Care AG (FMS): Price and Financial Metrics
Fresenius Medical Care AG (FMS)
Today's Latest Price: $42.49 USD
Updated Jul 10 6:30pm
Add FMS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 67 in Medical - Services
See all "A" rated Strong Buy stocks
FMS Stock Summary
- FMS has a market capitalization of $25,352,019,410 -- more than approximately 92.71% of US stocks.
- With a year-over-year growth in debt of 60.79%, Fresenius Medical Care AG & Co KGaA's debt growth rate surpasses 82.53% of about US stocks.
- In terms of volatility of its share price, FMS is more volatile than merely 6.7% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Fresenius Medical Care AG & Co KGaA are ADM, MKC, TSN, NTR, and CRH.
- Visit FMS's SEC page to see the company's official filings. To visit the company's web site, go to www.freseniusmedicalcare.com.
FMS Stock Price Chart Technical Analysis Charts
FMS Price/Volume Stats
| Current price | $42.49 | 52-week high | $44.47 |
| Prev. close | $42.36 | 52-week low | $29.17 |
| Day low | $42.06 | Volume | 147,434 |
| Day high | $42.57 | Avg. volume | 362,633 |
| 50-day MA | $41.68 | Dividend yield | 1.06% |
| 200-day MA | $37.51 | Market Cap | 25.35B |
Fresenius Medical Care AG (FMS) Company Bio
Fresenius Medical Care provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease, and other health care services. The company was founded in 1996 and is based in Bad Homburg, Germany.
FMS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $42.49 | $92.7 | 115% |
Below please find a table outlining a discounted cash flow forecast for FMS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Fresenius Medical Care AG & Co KGaA ranked in the 63th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Fresenius Medical Care AG & Co KGaA, consider:
- The company's balance sheet shows it gets 48% of its capital from equity, and 52% of its capital from debt. Notably, its equity weight is greater than merely 14.73% of US equities in the Healthcare sector yielding a positive free cash flow.
- Fresenius Medical Care AG & Co KGaA's weighted average cost of capital (WACC) is 6%; for context, that number is higher than only 3.11% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 111% |
| 1% | 113% |
| 2% | 115% |
| 3% | 117% |
| 4% | 119% |
| 5% | 122% |
RSCF, AMPH, DVA, EGRX, and CHE can be thought of as valuation peers to FMS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...